TREX BIO
TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us to identify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis.
TREX BIO
Industry:
Bioinformatics Biopharma Biotechnology
Founded:
2018-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.trex.bio
Total Employee:
11+
Status:
Active
Total Funding:
85 M USD
Technology used in webpage:
Euro Cloudflare Hosting
Similar Organizations
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
CAMP4 Therapeutics
CAMP4 Therapeutics is a biotechnology company that uses RNA to restore healthy gene expression.
Catamaran Bio
Catamaran Bio is a biotechnology company that specializes in allogeneic immune cell therapies.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Swiftscale Biologics
Swiftscale Biologics uses cell-free protein synthesis to enable the next generation of protein therapeutics.
Ultivue
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing.
Current Advisors List
Board_member
Board_member
2022-03-01
Board_member
2018-01-01
Board_observer
2022-03-01
Current Employees Featured
Johnston Erwin CEO @ TRex Bio
CEO
2021-05-01
Ovid Trifan Chief Medical Officer @ TRex Bio
Chief Medical Officer
Melanie Kleinschek Chief Scientific Officer @ TRex Bio
Chief Scientific Officer
Founder
Investors List
Johnson & Johnson Innovation – JJDC
Johnson & Johnson Innovation – JJDC investment in Series A - TRex Bio
Laurion Capital Management
Laurion Capital Management investment in Series A - TRex Bio
Pfizer Venture Investments
Pfizer Venture Investments investment in Series A - TRex Bio
Alexandria Venture Investments
Alexandria Venture Investments investment in Series A - TRex Bio
Eli Lilly & Company Foundation
Eli Lilly & Company Foundation investment in Series A - TRex Bio
SV Health Investors
SV Health Investors investment in Series A - TRex Bio
Polaris Partners
Polaris Partners investment in Series A - TRex Bio
Eli Lilly
Eli Lilly investment in Series A - TRex Bio
Pfizer Venture Investments
Pfizer Venture Investments investment in Series A - TRex Bio
SV Health Investors
SV Health Investors investment in Series A - TRex Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2021-06-22 | TRexBio has Jurassic day picking up ex-Lilly VP as CEO, snagging Big Pharma funding |
Official Site Inspections
http://www.trex.bio Semrush global rank: 7.11 M Semrush visits lastest month: 890
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "TRex Bio"
TRex Bio
Nov 13, 2024 The foundation of our drug discovery and development efforts is our unique, human tissue-based Deep Biology Platform that allows us to map T reg behavior in human tissue to dysregulation in disease.. We are using our …See details»
TRex Bio - Crunchbase Company Profile & Funding
Organization. TRex Bio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying …See details»
TRex Bio Company Profile: Overview and Full News Analysis
TRex Bio, a California biotechnology company thats partnered with Eli Lilly and Johnson & Johnson, has raised $84 million in a Series B round . The funds will be used to push TRB-061 …See details»
Trex Bio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
SOUTH SAN FRANCISCO, CA, USA I June 26, 2024 I TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary …See details»
TRexBio Company Profile 2024: Valuation, Funding & Investors
TRexBio General Information Description. Developer of biotechnology therapeutics designed to treat immune-mediated diseases. The company maps human tissue's behavior to disease …See details»
TRex Bio - Funding, Financials, Valuation & Investors - Crunchbase
TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying human tissues. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much …See details»
TRex Bio - The Org
TRex Bio 0 followers TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for …See details»
TRexBio Company Profile | Management and Employees List
Trex.bio TRexBio Profile and History Founded in 2018, based out of San Francisco, California, TRexBio is a discovery stage biotechnology company leveraging cutting edge computational …See details»
TRexBio Company Overview, Contact Details & Competitors | LeadIQ
Mar 8, 2022 TRex Bio, Inc. announced that it has received $84 million in an oversubscribed round of funding led by new investor, Delos Advisors Limited on November 13, 2024. Nov 12, …See details»
TRex Bio - Contacts, Employees, Board Members, Advisors & Alumni
Organization. TRex Bio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 3. Number of Board …See details»
TRexBio - Company Profile - Tracxn
Nov 21, 2024 TRex Bio raises $84M to compete in crowded immune drug fieldBioPharmaDive • Nov 13, 2024 • TRexBio, Delos Capital, Polaris Partners, Johnson & Johnson and 1 other …See details»
TRexBio Announces Collaboration and License Agreement with …
SOUTH SAN FRANCISCO, January 9, 2023 – TRex Bio, Inc., (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today …See details»
TRexBio - Products, Competitors, Financials, Employees, …
TRex Bio – a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics – announced the closing of an oversubscribed $84 million Series B …See details»
TRexBio Financial Overview, Employee Count, and Competitors
TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop …See details»
TRB-051 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 SOUTH SAN FRANCISCO, CA, USA I June 26, 2024 I TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary …See details»
TRex Bio - Updates, News, Events, Signals & Triggers - Crunchbase
Organization. TRex Bio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Growth Insight Details. Powered by AI . Edit Growth …See details»
TRB-031 - Drug Targets, Indications, Patents - Synapse
TRB-031, Initially developed by Trex Bio, Inc., Now, its global highest R&D status is Discovery, Therapeutic Areas: Immune System Diseases, Active Indication: Immune ...See details»
Our Science | TRex Bio
The trex approach There is a growing body of scientific research highlighting the unique role of immune cells within the tissue environment. Leveraging a suite of modern computational tools …See details»
Pipeline | TRex Bio
Notably, we work with Eli Lilly across 3 programs that have been identified and characterized leveraging TRex’s Deep Biology platform : TRB-031, TRB-041, and TRB-051. We also entered …See details»